Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01586910 · ClinicalTrials.gov registry record · NA
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
A NA study of Severe Aortic Stenosis, sponsored by Medtronic Cardiovascular.
- Active
- Registry status
- NA
- Development phase
- 1,746
- Enrollment target
- 20
- Study locations
NCT01586910 is a NA study of Severe Aortic Stenosis that is active but no longer recruiting, run by Medtronic Cardiovascular. The registered enrollment target is 1,746 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT01586910, a NA study of Severe Aortic Stenosis, is active but no longer recruiting, sponsored by Medtronic Cardiovascular.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,746 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at intermediate surgical risk by randomizing patients to either Surgical Aortic Valve Replacement (SAVR) or TAVI with the Medtronic CoreValve® System. Single Arm: The purpose of this trial is to evaluate the safety and effectiveness of transcatheter aortic valve implementation (TAVI) in patients with severe symptomatic Aortic Stenosis (AS) at intermediate surgical risk with TAVI. This is a non-randomized phase of the pivotal clinical trial.
Conditions Studied
Interventions
- DEVICE Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
- PROCEDURE Surgical Aortic Valve Replacement (SAVR)
- DEVICE Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Study Locations (20)
California
- Cedars-Sinai Medical Center - Hollywood
- Scripps Green Hospital - La Jolla
- Keck Medical Center of USC - Los Angeles
- El Camino Hospital - Mountain View
- VA Palo Alto Health Care System - Palo Alto
- Southern California Permenente Medical Group - Pasadena
- Stanford University Medical Center - Stanford
Florida
- Morton Plant Hospital - Clearwater
- University of Miami - Coral Gables
- Delray Medical Center - Delray Beach
Connecticut
- Hartford Hospital - Hartford
- Yale New Haven Hospital - New Haven
Georgia
- Emory University - Atlanta
- Piedmont Healthcare, Inc. - Atlanta
Arizona
- Banner Good Samaritan Medical Center - Phoenix
District of Columbia
- Washington Hospital Center - Washington D.C.
Hawaii
- The Queen's Medical Center - Honolulu
Illinois
- Loyola University of Chicago - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,746 participants |
| Start Date | 2012-04 |
| Est. Completion | 2026-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01586910
The ClinicalTrials.gov registry entry for NCT01586910 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,746 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Aortic Stenosis appearing as the primary indexed condition, and to 3 interventions - of which Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI) is the first listed.
NCT01586910 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01586910 about?
NCT01586910 is a clinical study titled "Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).". The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at intermediate surgical risk by randomizing patients to either Surgical Aortic Valve Replacement (SAVR) or TAVI with the Med...
What is the current status of trial NCT01586910?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,746 participants. The study started on 2012-04. Estimated completion is 2026-11.
What conditions does trial NCT01586910 study?
This clinical trial studies the following conditions: Severe Aortic Stenosis.
What interventions are being tested in trial NCT01586910?
The interventions under investigation include: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI) (DEVICE), Surgical Aortic Valve Replacement (SAVR) (PROCEDURE), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI) (DEVICE).
Who is sponsoring clinical trial NCT01586910?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01586910 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Aortic Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.